WordNet

swelling from excessive accumulation of watery fluid in cells, tissues, or serous cavities (同)oedema, hydrops, dropsy

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非心原性肺水腫 noncardiogenic pulmonary edema
2. 心原性肺水腫の病態生理 pathophysiology of cardiogenic pulmonary edema
3. 高地肺水腫 high altitude pulmonary edema
4. 神経原性肺水腫 neurogenic pulmonary edema
5. ドラッグを注射している患者における肺疾患の概要 overview of pulmonary disease in injection drug users

Initiating Acute Dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study.

Lim CC1, Tan CS, Kaushik M, Tan HK.
Nephrology (Carlton, Vic.).Nephrology (Carlton).2014 Nov 13. doi: 10.1111/nep.12364. [Epub ahead of print]
AIM: Optimal timing for acute renal replacement therapy (ARRT) initiation in critically ill patients with acute kidney injury (AKI) is unclear. We aimed to evaluate outcomes in patients who initiated ARRT for traditional indications versus those who met Acute Kidney Injury Network (AKIN) criteria wi
PMID 25395245

Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis.

Povey H, Vundru R, Junglee N, Jibani M.
Clinical nephrology.Clin Nephrol.2014 Nov;82(5):326-31. doi: 10.5414/CN107958.
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) which encompasses hemolytic anemia, thrombocytopenia, and organ impairment. Around 10% of cases are atypical HUS (aHUS), a rare disease with poor outcomes caused by uncontrolled activation of the alternative complement pathway. Th
PMID 23557793

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene.

Román-Ortiz E1, Mendizabal Oteiza S, Pinto S, López-Trascasa M, Sánchez-Corral P, Rodríguez de Cordoba S.
Pediatric nephrology (Berlin, Germany).Pediatr Nephrol.2014 Jan;29(1):149-53. doi: 10.1007/s00467-013-2591-8. Epub 2013 Aug 24.
BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. Outcomes of kidney transplantation are poor owing to aHUS recurrence and loss of graft. Patients carrying CFH mutations or CFH/CFHR1 hybrid genes pres
PMID 23982707